Amicus Therapeutics Target of Unusually High Options Trading (FOLD)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the target of some unusual options trading activity on Wednesday. Traders purchased 5,966 call options on the stock. This is an increase of 1,576% compared to the average volume of 356 call options.
FOLD has been the topic of several recent analyst reports. Leerink Swann reaffirmed a “buy” rating and set a $20.00 price objective (up from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Bank of America increased their price objective on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Chardan Capital reaffirmed a “buy” rating and set a $18.50 price objective (up from $16.50) on shares of Amicus Therapeutics in a report on Thursday, October 5th. Zacks Investment Research raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Tuesday, October 10th. Finally, BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $17.81.
In other Amicus Therapeutics news, SVP Daphne Quimi sold 7,000 shares of the stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $99,750.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Hung Do sold 50,194 shares of the stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $715,264.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 826,114 shares of company stock worth $11,791,184. Insiders own 3.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of FOLD. Janus Henderson Group PLC acquired a new stake in shares of Amicus Therapeutics in the second quarter valued at about $70,762,000. Farallon Capital Management LLC acquired a new stake in shares of Amicus Therapeutics in the second quarter valued at about $30,210,000. Eagle Asset Management Inc. acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at about $40,450,000. Jennison Associates LLC raised its position in shares of Amicus Therapeutics by 9.4% in the third quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock valued at $147,362,000 after buying an additional 838,267 shares during the last quarter. Finally, Allianz Asset Management GmbH acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at about $11,381,000.
Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at $14.91 on Friday. The company has a market cap of $2,480.00, a PE ratio of -8.15 and a beta of 1.72. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics has a 12-month low of $5.07 and a 12-month high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million during the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. Amicus Therapeutics’s quarterly revenue was up 419.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.33) earnings per share. sell-side analysts anticipate that Amicus Therapeutics will post -1.56 EPS for the current fiscal year.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.